FDA approves Sovaldi for chronic hepatitis C
"The U.S. Food and Drug Administration today approved Sovaldi (sofosbuvir) to treat chronic hepatitis C virus (HCV) infection. Sovaldi is the first drug that has demonstrated safety and efficacy to treat certain types of HCV infection without the need for co-administration of interferon.
Sovaldi is the second drug approved by the FDA in the past two weeks to treat chronic HCV infection. On November 22, the FDA approved Olysio (simeprevir)."
To read more, please visit:
Also, please see the attached New York Times article, "F.D.A. Approves Pill to Treat Hepatitis C."